Ongoing WARfarin and Coronary STENTing (WAR-STENT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00722319 |
Recruitment Status
: Unknown
Verified January 2010 by War-Stent Investigators.
Recruitment status was: Active, not recruiting
First Posted
: July 25, 2008
Last Update Posted
: August 12, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Acute Coronary Syndrome Atrial Fibrillation |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment. |
Study Start Date : | March 2009 |
Actual Primary Completion Date : | July 2010 |
Estimated Study Completion Date : | October 2011 |

Group/Cohort |
---|
A
Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
|
- Incidence of major/minor bleeding + adverse cardiac events (i.e., need for urgent re-revascularization, myocardial infarction, death) + arterial/venous thrombosis/thromboembolism [ Time Frame: 1, 3, 6 and 12 months ]
- Incidence of major/minor bleeding [ Time Frame: 1, 3, 6 and 12 months ]
- Adverse cardiac events (i.e., need for urgent re-revascularization, myocardial infarction, death) [ Time Frame: 1, 3, 6 and 12 months ]
- Stent thrombosis [ Time Frame: 1, 3, 6 and 12 months ]
- Arterial/venous thromboembolism; [ Time Frame: 1, 3, 6 and 12 months ]
- Blood transfusions [ Time Frame: 1, 3, 6 and 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with ongoing warfarin treatment.
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00722319
Italy | |
Division of Cardiology | |
Bologna, Italy, 40133 |
Study Director: | Andrea Rubboli, MD | Division of Cardiology, Maggiore Hospital, Bologna |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Aldo P. Maggioni, Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) |
ClinicalTrials.gov Identifier: | NCT00722319 History of Changes |
Other Study ID Numbers: |
WS-1 |
First Posted: | July 25, 2008 Key Record Dates |
Last Update Posted: | August 12, 2011 |
Last Verified: | January 2010 |
Keywords provided by War-Stent Investigators:
oral anticoagulation warfarin percutaneous coronary intervention stent antiplatelet agents |
Additional relevant MeSH terms:
Atrial Fibrillation Acute Coronary Syndrome Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases |
Pathologic Processes Myocardial Ischemia Vascular Diseases Warfarin Anticoagulants |